Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.82 |
| ▸ | HRH2 | P25021 | 9/20 | 0.82 |
| ▸ | HRH1 | P35367 | 9/20 | 0.82 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1715600 | 0.94 | HRH3 (0.92) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL1714312 | 0.87 | HRH3 (0.71) | HRH3HRH2HRH1KCNA5 | |
| SCHEMBL1715421 | 0.86 | HRH3 (0.93) | HRH3HRH2HRH1MEN1 | |
| SCHEMBL19189997 | 0.86 | HRH3 (0.63) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL4874490 | 0.84 | HRH3 (0.82) | HRH3HRH2HRH1KCNA5 | |
| SCHEMBL15071682 | 0.83 | HRH3 (0.70) | HRH3HRH2HRH1SIGMAR1KCNA5 | |
| SCHEMBL5623066 | 0.83 | HRH3 (0.79) | HRH3HRH2HRH1KCNA5MEN1 | |
| SCHEMBL227297 | 0.83 | HRH3 (0.85) | HRH3HRH2HRH1 | |
| SCHEMBL5214779 | 0.83 | HRH3 (1.00) | HRH3HRH2HRH1 | |
| SCHEMBL19047571 | 0.81 | HRH3 (0.68) | HRH3HRH2HRH1SIGMAR1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794595-B1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-8859559-B2 | Substituted pyrazines and their use in the treatment of disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859559-B2 | Substituted pyrazines and their use in the treatment of disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| WO-2013092674-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | HRH3 534/4885HRH2 203/4885HRH1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.